Short Report on Pfizer Stock

By Tamara Parker • Tuesday, November 28 18:23 • Permanent Link

Large-cap Health Care company Pfizer has moved -1.5% so far today on a volume of 29,092,197, compared to its average of 28,696,074. In contrast, the S&P 500 index moved 0.0%.

Pfizer trades -25.96% away from its average analyst target price of $40.1 per share. The 21 analysts following the stock have set target prices ranging from $32.0 to $75.0, and on average have given Pfizer a rating of buy.

If you are considering an investment in PFE, you'll want to know the following:

Pfizer's current price is -23.0% below its Graham number of $38.58, which implies the stock has a margin of safety
Pfizer has moved -39.0% over the last year, and the S&P 500 logged a change of 16.0%
Based on its trailing earnings per share of 1.83, Pfizer has a trailing 12 month Price to Earnings (P/E) ratio of 16.2 while the S&P 500 average is 15.97
PFE has a forward P/E ratio of 9.4 based on its forward 12 month price to earnings (EPS) of $3.15 per share
The company has a price to earnings growth (PEG) ratio of -1.56 — a number near or below 1 signifying that Pfizer is fairly valued compared to its estimated growth potential
Its Price to Book (P/B) ratio is 1.73 compared to its sector average of 4.16
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide.
Based in New York, the company has 83,000 full time employees and a market cap of $167.64 Billion. Pfizer currently returns an annual dividend yield of 5.4%.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.